Objective: Biomarkers are needed to improve the sensitivity and accuracy of diagnosis, and also prognosis, in individuals with early Alzheimer disease (AD). Measures of brain structure and diseaserelated proteins in the cerebrospinal fluid (CSF) have been proposed as biomarkers, yet relatively little is known about the relationships between such measures. The present study was conducted to assess the relationship between CSF Ab and tau protein levels and longitudinal measures of hippocampal structure in individuals with and without very mild dementia of the Alzheimer type.
(Alzheimer Dis Assoc Disord 2012; 26:314-321) A ggregation of the amyloid-b (Ab) peptide in amyloid plaques and tau in neurofibrillary tangles are the histopathologic hallmarks of Alzheimer disease (AD) and are used to confirm the clinical diagnosis of dementia of the Alzheimer type (DAT) in postmortem brain autopsy. Postmortem studies have shown that by the time dementia becomes apparent plaques and tangles are prominent in the medial temporal lobe and cortex. 1, 2 In individuals with DAT, levels of cerebrospinal fluid (CSF) Ab 1 to 42 (Ab ) are reduced and tau proteins are elevated. 3 Moreover, in such patients, lower CSF Ab and higher tau levels have been correlated with in vivo cerebral atrophy, 4, 5 with cortical amyloid load as assessed by amyloid imaging, 6, 7 and with increased postmortem plaque and tangle pathology. 8, 9 In a recent cross-sectional analysis of the relationship between CSF and neuroanatomical measures, Fagan et al 10 suggested that lower Ab 1-42 levels were more strongly associated with brain atrophy in cognitively normal individuals during early amyloid accumulation, whereas higher tau and phosphorylated tau 181 (p-tau 181 ) levels were more strongly associated with brain atrophy in cognitively impaired individuals. Finally, several studies have shown that CSF Ab , either alone or combined with tau measures (as ratios or linear combination), can be useful for predicting conversion to DAT. 11, 12 In the current study, we selected participants from a prior study of CSF biomarkers 10 with longitudinal neuroimaging data to investigate the effect of baseline disease pathology as measured by CSF proteins on longitudinal changes of brain structure. On the basis of our previous study, 10 we hypothesized that CSF Ab 1-42 levels would be correlated with progressive changes in hippocampal structure in participants with DAT. Further, because we previously found that deformations of the hippocampal CA1 area most powerfully discriminated participants with DAT from cognitively normal individuals, [13] [14] [15] we hypothesized that the strongest correlations would be found between CSF Ab 1-42 levels and inward deformation of the CA1 area of the hippocampal surface, but not in CSF Ab 40 , tau 181 , or p-tau 181 .
METHODS

Participants
The participants of this study were selected from previous investigations of relationships between whole-brain measures and levels of CSF biomarkers. 10 All participants were rated according to the Clinical Dementia Rating scale (CDR) 16 and underwent an independent diagnosis and staging of DAT according to NINCDS-ADRDA criteria. 17 The previous study included 69 cognitively normal (CDR 0) and 21 very mild AD (CDR 0.5 with a concurrent diagnosis of DAT) individuals, all scanned on a 1.5 T scanner. Investigators elsewhere may characterize at least some of these CDR 0.5 DAT individuals as having mild cognitive impairment (MCI) rather than AD. We have undergone a scanner field upgrade since the initial study; therefore, only a small number of participants who had longitudinal MR data on the 1.5 T scanner platform were included in this study. CSF assessments took place within 2 years of initial scanning. Previous studies of longitudinal changes of CSF have reported mixed results: whereas some have reported increases in p-tau in individuals with more severe cognitive impairments at baseline, 18, 19 the majority reported that CSF biomarkers remained stable over similar intervals. [20] [21] [22] [23] APOE4 allele status was also obtained for these participants. The final sample of 11 CDR 0 and 13 CDR 0.5 participants for this study was small but relatively well matched (Table 1) .
CSF Collection, Processing, and Biomarker Measurement
CSF (20 to 30 mL) was collected by standard lumbar puncture (LP) in polypropylene tubes at 08:00 AM after an overnight fast as described previously. 6 Samples from blood contamination were gently inverted to remove possible gradient effects, briefly centrifuged at low speed to pellet any cellular elements, and aliquoted (500 mL) into polypropylene tubes before freezing at À 841C. Total tau, p-tau 181 , and Ab 1-42 were analyzed using a commercial enzyme-linked immunosorbent assay (Innogenetics, Ghent, Belgium) performed on aliquots after a single thaw. CSF Ab was assayed by an enzyme-linked immunosorbent assay as described elsewhere. 24 
Imaging and Mapping of Hippocampus
All MR scans were collected on a Siemens 1.5 T VISION system. The scanning protocol included four 3D T1-weighted MPRAGE scans (voxel resolution = 1 mmÂ 1 mmÂ1.25 mm, TR = 9.7 ms, TE = 4.0 ms, flip angle = 101, scan time = 6.5 min). Scans for each participant were aligned with the first scan and averaged to create a low-noise image. 25 For mapping the volume and surface of the hippocampus, images were processed using the FreeSurfer+ Large-Deformation Diffeomorphic Metric Mapping (FS+LDDMM) pipeline as described previously. 26, 27 This process consisted of: (1) FreeSurfer 28 labeling and initial affine registration that generated rough hippocampal segmentation; (2) intensity normalization with histogram matching that ensured similar tissue-type intensities; and (3) LDDMM-based diffeomorphic mapping, 29 which produced smooth transformations. The template was the same cognitively normal 69-year-old male CDR 0 participant studied previously, 15 who was obtained from the same source as the other subjects but not included in the data analysis.
For mapping hippocampal surfaces in longitudinal scans, FS+LDDMM was performed on each participant with the initial scan as the template and follow-up scans as targets. The initial surface was then carried into each follow-up scan through diffeomorphic transformation.
Hippocampal Volume, Surface Variation, and Change
For each hippocampal surface at each timepoint, volume was calculated as the enclosed volume of the mapped surface. Deformation from an external reference 15 was then calculated at each surface point after rigid registration of all surfaces to the reference, from which average deformation for the CA1, subiculum, and CA2-4+DG (CA2, 3, 4, and dentate gyrus combined) subfields was calculated according to previously described methods. 15, 26 Negative and positive values for these measures represented inward and outward surface deformation, respectively. Normalized whole-brain volumes were computed as the proportion of all voxels occupied by gray and white matter (equivalent to 100%À%CSF) voxels, yielding a unit that represented the proportion of estimated total intracranial volume. 25 Annualized rates of change of the hippocampal volume, subfield deformation, and normalized whole-brain volumes were calculated by performing a linear regression of each measure at all timepoints against time elapsed since baseline.
Data Analysis
Group differences in the rates of change and initial measures of hippocampal volume and subfield deformation were examined with general linear models using SAS 9.1, 30 where left and right hemispheres were treated as repeated measures. Because no significant hemisphere asymmetry was observed during the analysis, we averaged left+right hemisphere slope measures for correlation analysis (Spearman's r) among hippocampal measures. We correlated hippocampal slopes with CSF measures in each group separately, partialling out APOE4 status and age, adjusting for multiple comparisons (a = 0.0125 for 4 structural variables). We also performed hierarchical regression using each of the CSF measures as the dependent variable and slopes of volume and CA1 as predictors to examine whether subfield measures accounted for significant variance beyond volume.
RESULTS
Demographics
At baseline, the 2 groups did not differ in age (t = À 0.52, df = 22, P = 0.61) or gender (w 2 = 2.7, P = 0.10). The MMSE scores for CDR 0 were significantly higher than that for CDR 0.5 (t = 2.7, df = 21, P = 0.014; 1 CDR 0 participant missing value). Nine of the 11 CDR 0 participants underwent an LP before scanning (7.9 ± 9.1 mo) and 2 underwent the same after scanning (16.0 ± 7.4 mo). Seven of the 13 CDR 0.5 participants underwent an LP before scanning (1.0 ± 1.1 mo) and 6 underwent the same after scanning (8.6 ± 6.8 mo) (w 2 = 2.1, P = 0.15). The 2 groups also did not differ in the time interval between LP and the date of initial scan (t = 1.6, df = 22, P = 0.13). Longitudinal MR scans were on average 1.77 ± 0.64 years apart, ranging from 0.31 to 3.32 years, with no difference in the scan interval between the 2 groups. Ten participants had no APOE4 alleles, whereas 4 CDR 0 participants and 10 CDR 0.5 participants had at least 1 APOE4 allele ( Table 1) .
Comparison of CSF and Anatomical Change
Group differences for the CSF and neuroanatomical measures are summarized in Table 2 . Consistent with the findings reported in Fagan et al, 10 CDR 0.5 participants had higher levels of tau (P = 0.013), p-tau 181 (P = 0.048), and lower levels of Ab 1-42 (P = 0.090, trend) but not Ab (P = 0.69). As expected, tau/Ab 1-42 (P = 0.0069) and p-tau 181 /Ab 1-42 (P = 0.016) ratios were higher in CDR 0.5 participants.
CDR 0.5 participants exhibited significantly accelerated decreases (ie, more negative annualized rates of change) in hippocampal volumes and more pronounced changes in inward deformation of the CA1, subiculum, and CA2-4+GD subfield surface zones as compared with CDR 0 participants, even after covarying baseline measures. Also, consistent with our previous findings in similar populations, 15 CDR 0.5 participants exhibited significantly smaller baseline hippocampal volumes and more inward deformation of the CA1 subfield surface zones as compared with CDR 0 participants. The CDR 0.5 participants exhibited significantly smaller initial whole-brain measure and accelerated whole-brain atrophy, as reported elsewhere in similar populations. 31, 32 Correlation Between CSF and Anatomical Change
Correlations between CSF and hippocampal change have been reported separately for the CDR 0.5 and CDR 0 participant groups in Table 3 . Significant correlations were found only for CDR 0.5 participants-lower levels of Ab 1-42 For CSF and whole-brain measures, P values were obtained from t tests. For hippocampal measures, P values were obtained from general linear models where left and right hemispheres were treated as repeated measures. P values below 0.05 are shown in bold.
CA1 indicates deformation for the CA1 subfield; SUB, deformation for the subiculum subfield; CA2-4+GD, deformation for the combined subfields of CA2, 3, 4, and dentate gyrus; CDR, Clinical Dementia Rating; CSF, cerebrospinal fluid; ICV, intracranial volume; nWBV, normalized whole-brain volumes. and higher tau/Ab 1-42 and p-tau 181 /Ab 1-42 ratios were correlated with higher rates of hippocampal volume reduction (ie, accelerated atrophy) and higher rates of inward deformation (ie, more negative change) of the CA1 subfield zone. Scatter plots that illustrate these correlations are shown in Figure 1 . Similar relationships with the other hippocampal subfield measures were not found (significance reported for P < 0.0125, adjusting for multiple comparisons). There were no significant correlations between tau, p-tau 181 , and Ab 1 À 40 measures as individual variables and rates of change in hippocampal volume or any subfield measures in the CDR 0.5 participants. Significance (highlighted with bold face) is reported with multiple comparison corrections at P = 0.0125 (see text). Partialling out age and/or APOE4 status resulted in similar correlation values and significance. We also conducted a robust multivariate outlier detection (http://www.math.yorku.ca/SCS/sssg/ outlier.html) on each anatomical variable, and found that there was only 1 CDR 0 outlier and 1 CDR 0.5 outlier in each case. Removing them from the analysis did not diminish the correlations.
CA1 indicates deformation for the CA1 subfield; SUB, deformation for the subiculum subfield; CA2-4+GD, deformation for the combined subfields of CA2, 3, 4, and dentate gyrus; CDR, Clinical Dementia Rating; CSF, cerebrospinal fluid. In CDR 0 participants, there were no significant correlations between CSF and hippocampal changes. Further, there were no significant correlations between any CSF measure and measures of baseline hippocampal structure in CDR 0.5 or CDR 0 participants (data not shown). The lack of correlation between CSF measures and initial hippocampal volumes was also found in a previously published study of a larger sample (from which this cohort has been obtained). 10 The relationships between CSF measures and rates of hippocampal surface deformation are visualized on the hippocampal surfaces with the subfield zones delineated (Fig. 2) . At each surface location, the slope of surface deformation was first computed by linear regression against time elapsed since baseline, and the correlation between this slope and the CSF measure was calculated. The surface locations clustered at 33 or more vertices (accounting for 0.5% or more total hippocampal surface area) with correlation coefficients Pr0.05 were colored on the hippocampal surface according to the color scale; those with P>0.05 or that did not reach clustering threshold were colored in green. These representations provided visual confirmation of the correlation between Ab 1-42 -related measures and inward deformation of the hippocampal surface approximating the CA1 subfield.
Volume slope
The rate of change of the hippocampal volume was correlated with that of CA1 (r = 0.96, P < 0.0001), subiculum (r = 0.85, P < 0.0001), and CA2-4+DG (r = 0.05). For Ab 1-42 , the hierarchical regression analysis showed that the CA1 slope did not account for significant variance beyond volume slope (P = 0.33); for tau/Ab 1-42 , it showed trend level (0.083); and for p-tau 181 /Ab 1-42 , it did account for significant variance beyond volume slope (P = 0.0076).
DISCUSSION
Our results suggest that lower CSF Ab 1-42 levels and higher tau/Ab 1-42 and p-tau 181 /Ab 1-42 ratios are correlated with hippocampal degeneration (ie, accelerated rates of hippocampal volume and specific subfield atrophies but not at the initial timepoint) in individuals with very mild DAT, but not in cognitively normal individuals. Our findings support prior reports of the relationships between lower CSF Ab 1-42 levels and increased rates of neurodegeneration of medial temporal lobe structures, including the hippocampus, in individuals with DAT. 5, 33, 34 Although initial tau and p-tau 181 levels exhibited some correlations with changes in hippocampal structure in both participant groups, these correlations did not survive multiple comparison correction. The lack of significant relationships between CSF tau measures and hippocampal degeneration within individuals with very mild DAT or cognitively normal individuals has also been reported elsewhere. [34] [35] [36] [37] Although tau is generally assumed to cause hippocampal atrophy, it is possible that tangle load and neurodegeneration may not have reached a level to elevate CSF tau measurement. Also, previously reported correlations between whole-brain volume and Ab 1-42 (but not tau) level in individuals who do not suffer from dementia 10 suggest that atrophy may also be caused by Ab 1-42 dysmetabolism early in AD. Indeed, the finding that Ab 1-42 and its related ratios, but not tau, were correlated with hippocampal atrophy further suggests that lowered Ab 1-42 level is a "necessary" but not sufficient condition for structural changes.
Similarly, the lack of significant association between APOE4 status and hippocampal volume loss has also been reported in normal and MCI subjects. 34 Finally, initial Ab 1 À 40 levels were not correlated with baseline or slope measures of hippocampal structure in either group. These findings are consistent with prior findings that Ab 1-42 is more prone to aggregation than Ab 1 À 40 38 and is therefore more closely associated with the pathogenesis of AD. 39 We were able to represent the correlations between Ab 1-42 levels and changes in hippocampal structure as regions on the hippocampal surface related to specific cellular subfields of the hippocampus: namely, the CA1 and subiculum (see also Fig. 2 ). This pattern of progressive inward deformation of the hippocampal surface involving the hippocampal CA1 subfield and subiculum was first reported by our group 14, 15, 26 and later confirmed by others in cross-sectional studies of AD, 37, [40] [41] [42] aging, 41 and AD-related cognitive decline. 43 However, the results of this study are the first to relate subfield patterns of structural change to CSF biomarkers of AD-in particular, measures related to Ab 1-42 and the tau/Ab 1-42 ratio. These findings are also consistent with the observed pattern of hippocampal pathology in postmortem studies of individuals with AD-that is, prominent neuronal degeneration in the hippocampal CA1 subfield- 2, 44, 45 which suggests that our longitudinal hippocampal mapping algorithm may help detect subtle neuroanatomical changes that are characteristic of AD. Thus, the measurement of change in the hippocampal structure, perhaps in combination with CSF Ab or ratios with tau and p-tau 181 , may be useful for constructing a biomarker of the underlying disease process in early-stage AD. Approximately 30% of cognitively normal individuals in the middle of their eighth decade have significant AD pathology, 2 whereas individuals designated as CDR 0.5 predictably progress to more severe dementia with time and, at autopsy, are highly likely (93%) to have histopathologic (ie, plaques and tangles) AD. 46 Because decreased CSF Ab 1-42 levels are associated with Ab aggregation in the brain, our finding that lower Ab 1-42 levels and higher tau(s)/Ab 1-42 ratios are related to accelerated hippocampal loss in the CDR 0.5 group, but not in the CDR 0 group, provides support for the role of Ab 1-42 as a key indicator of progression of the disease process underlying AD. Moreover, evidence of increases in CSF tau levels in the setting of decreased Ab 1-42 levels indicates that a neurodegenerative process is taking place. In the current study, the presence of a strong association between Ab 1-42 -related measures and longitudinal changes, but not cross-sectional differences, in the hippocampal structure suggests that longitudinal changes in brain structure are highly sensitive indicators of AD-related neurodegeneration. Also, Fagan et al 10 reported that CSF measures did not correlate with hippocampal volumes sampled at a single timepoint, perhaps suggesting that nonspecific genetic or environmental factors can obscure disease-related relationships at single timepoints. Our findings that CSF Ab 1-42 levels were not related to longitudinal measures of hippocampal change in cognitively normal individuals are consistent with recent reports that there is no association between Ab burden and longitudinal hippocampal atrophy in these individuals. 47 Also, even though the CA1 slope was highly correlated with the volume slope, it accounted for varying degrees of significant variance beyond the volume slope for the There are several limitations to our study. First, the small sample size limits our ability to detect small correlations with sufficient power. For any given CSF marker as a predictor, the power to detect a correlation with R 2 = 0.2 in the 11 CDR 0 participants would be 0.29, whereas for the 13 CDR 0.5 participants with R 2 = 0.48 the power is 0.76. The small sample size further limits our ability to generalize and interpret the findings for the subiculum, in which the moderate correlations did not reach statistical significance after correction for multiple comparisons ( Table 3 ). In addition, improving balance between male and female participants in the CDR 0 group may also help the interpretability of our findings in comparison with the correlations observed in the CDR 0.5 group, as Hua et al 48 showed a faster rate of wholebrain and medial temporal lobe volume decline in women as compared with men. Second, we cannot determine whether the correlations we observed reflect a direct relationship between hippocampal degeneration and amyloid deposition within the structure, or a more indirect relationship with amyloid deposition at distant cortical locations (perhaps in regions that project directly or indirectly into the hippocampus). Gross CSF measures are unlikely to capture specific regional amyloid information. Postmortem confirmation that the individuals assessed as CDR 0.5 had AD was not available at the time of preparation of this paper. Third, the time of CSF collection and MR scanning was on average 4 (CDR 0.5) to 9 (CDR 0) months apart; thus, our results should be interpreted with further caution as the predictability of one measure for the other becomes unclear because of the time lag.
Also, our study did not have sufficient sample size to allow further investigation of the cognitively normal participants based on Ab 1-42 cut-offs. Notably, the results of some prior studies have suggested that, above a certain threshold, disease-related CSF measures may not be related to brain structural changes 49 or age. 2 Finally, we did not have longitudinal CSF measures on all participants, and in one study these levels were associated with longitudinal decreases in hippocampal volumes in individuals with MCI 5 (n = 7). Such analyses may be possible in the future as we continue to follow up our participants over time.
In conclusion, despite the small sample size, we found that lower CSF Ab 1-42 levels and higher tau/Ab 1-42 and p-tau 181 /Ab 1-42 ratios were related to progressive hippocampal degeneration in individuals with very mild DAT, and we related these CSF measures to patterns of structural change in specific hippocampal subfields. Future studies that include longitudinal CSF measures, larger sample sizes, and brain structure measures beyond the medial temporal lobe, as suggested by Fjell et al, 33 are needed to further elucidate the relationships between CSF biomarkers and dementia-related neurodegeneration.
